This invention provides isolated nucleic acid molecules encoding a human dopamine D.sub.1 receptor, isolated proteins which are human dopamine D.sub.1 receptor, vectors comprising isolated nucleic acid molecules encoding a human dopamine D.sub.1 receptor, mammalian cells comprising such vectors, antibodies directed to a human dopamine D.sub.1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human dopamine D.sub.1 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human dopamine D.sub.1 receptor, pharmaceutical compounds related to human dopamine D.sub.1 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant human dopamine D.sub.1 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving a human dopamine D.sub.1 receptor.
This application is a continuation of U.S. Ser. No. 09/168,510, filed Oct. 8, 1998, now U.S. Pat. No. 6,468,767, issued Oct. 22, 2002, which is a divisional of U.S. Ser. No. 07/969,267, filed Oct. 5, 1993, now U.S. Pat. No. 5,882,855, issued Mar. 16, 1999, national stage under Section 371 of PCT International Application No. PCT/US91/04858, filed Jul. 10, 1991 on behalf of Synaptic Pharmaceutical Corporation, claiming priority of, and a continuation-in-part of, U.S. Ser. No. 07/551,448, filed Jul. 10, 1990, now abandoned, the contents of which are hereby incorporated by reference into the present disclosure.
